Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 1/20 | 0.38 |
| ▸ | DPP4 | P27487 | 16/20 | 0.37 |
| ▸ | DPP7 | Q9UHL4 | 16/20 | 0.37 |
| ▸ | DPP9 | Q86TI2 | 4/20 | 0.37 |
| ▸ | DPP8 | Q6V1X1 | 5/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | DRD4 | P21917 | 1/20 | 0.36 |
| ▸ | DRD3 | P35462 | 1/20 | 0.36 |
| ▸ | RORC | P51449 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3558684 | 0.85 | NAMPT (0.43) | KDM1ADPP4DPP7DPP9DPP8 | |
| SCHEMBL2198579 | 0.85 | KDM4E (0.39) | — | |
| SCHEMBL13504603 | 0.85 | KDM4E (0.39) | — | |
| SCHEMBL2198755 | 0.84 | CCR5 (0.39) | RORCKCNH2 | |
| SCHEMBL3554859 | 0.81 | MAPK1 (0.44) | DPP4DPP7RORC | |
| SCHEMBL2196452 | 0.79 | OPRD1 (0.41) | — | |
| SCHEMBL2196621 | 0.77 | DHODH (0.32) | — | |
| SCHEMBL2199776 | 0.76 | CHRNB4 (0.39) | — | |
| SCHEMBL3549751 | 0.76 | NAMPT (0.43) | KCNH2 | |
| SCHEMBL2202199 | 0.74 | KMT2A (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7977336-B2 | Aminopyrimidine derivatives as PLK1 inhibitors | BANYU PHARMACEUTICAL CO. LTD (JP) | 2011-07-12 | — | — | US | disclosed |
| EP-2116543-A1 | NOVEL AMINOPYRIMIDINE DERIVATIVE AS PLK1 INHIBITOR | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-11-11 | — | — | EP | disclosed |
| US-20080305081-A1 | Novel aminopyrimidine derivatives as PLK1 inhibitors | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2008-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080305081-A1 | Novel aminopyrimidine derivatives as PLK1 inhibitors | PLK1, AURKA, CDK1 | KDM1A 1412/4885DPP4 3044/4885DPP7 2788/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.